Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 May 2019Website:
http://www.nextcure.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 01 Jul 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
NXTC Latest News
BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The trial evaluated the combination in immune checkpoint inhibitor (ICI) naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer and demonstrated clinical activity in these hard-to-treat cancers. The data will be presented in a poster session by clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What type of business is NextCure?
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
What sector is NextCure in?
NextCure is in the Healthcare sector
What industry is NextCure in?
NextCure is in the Biotechnology industry
What country is NextCure from?
NextCure is headquartered in United States
When did NextCure go public?
NextCure initial public offering (IPO) was on 09 May 2019
What is NextCure website?
https://www.nextcure.com
Is NextCure in the S&P 500?
No, NextCure is not included in the S&P 500 index
Is NextCure in the NASDAQ 100?
No, NextCure is not included in the NASDAQ 100 index
Is NextCure in the Dow Jones?
No, NextCure is not included in the Dow Jones index
When does NextCure report earnings?
The next expected earnings date for NextCure is 02 August 2024